Navigation Links
Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
Date:10/25/2011

t of blepharospasm, a neurological condition that, if untreated, can cause significant disability."

The first poster presented at the AAO meeting, titled "Dosing Profile of XEOMIN (incobotulinumtoxinA) During Long-Term, Open-Label Treatment of Benign Essential Blepharospasm," evaluated the repeat-dosing profile of XEOMIN for up to 48 weeks, including the inter-injection interval, during an open-label extension (OLEX) of the Phase III randomized, double-blind trial that evaluated XEOMIN versus placebo. Although the injection frequency varied during the OLEX and many participants received injections at less than 12-week intervals, the investigator-determined dosing profile of XEOMIN remained similar to the initial single-treatment study, which was based on prior treatment with Botox®. [PO440, Oct. 24, 2011, 2 – 3:30 p.m. ET, Hall A1]

The second poster presented at the AAO meeting, titled "Adverse Event (AE) Profile of XEOMIN (incobotulinumtoxinA) in the Benign Essential Blepharospasm (BEB) Clinical Trials Program," assessed the AE profile of XEOMIN across two single-treatment trials (one versus placebo and one versus Botox®), as well as one repeat-treatment study (OLEX of the Phase III placebo-controlled study). [PO441, Oct. 24, 2011, 2 – 3:30 p.m. ET, Hall A1]

"Our community is always interested in learning more about XEOMIN and we are pleased to see these important data published in a prestigious journal and presented at the American Academy of Ophthalmology meeting. Merz has taken a strong interest in the blepharospasm community and the Company's commitment to educational programming is welcomed by the Benign Essential Blepharospasm Research Foundation," said Mary Lou (Koster) Thompson, BEBRF President.

About The Phase III Placebo-controlled Study and OLEXThe Phase III, randomized, placebo-controlled, double-blind study published in the journal Movement Disorders evaluated blepharospasm patients
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
2. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
3. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
5. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
6. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ... Disease Diagnostics Market by Product, Application, Technology, End User ... offering. , The infectious disease diagnostics market ... reach $18,156.2 million by 2019 from $12,422.8 million in ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the ... Product & by End User - Global Forecast to 2019" ... allergy diagnostics market is valued at $1,228.58 million in 2014 ... to reach $2,230.72 million by 2019. Allergy diagnostics is used ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/tl6pqb/xray_detectors ) ... by Detector Type, Applications & by FPD Panel Size - ... , The X-ray detectors market is a growing ... its inception, such as a shift from film to filmless ...
Breaking Medicine Technology:Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 2Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 3
... March 23, 2011 DATATRAK International, Inc. (OTCQX: ... global eClinical solutions for the clinical trials industry, ... Association,s EuroMeeting. The 23rd Annual EuroMeeting will address ... evaluating the benefits new science and technologies are ...
... (NYSE: BSX ) today announced that it will ... 60th Annual Scientific Session of the American College of Cardiology/i2 ... on its Cardiology, Rhythm and Vascular (CRV) Group initiatives involving ... to begin at 6 p.m. CT and adjourn at approximately ...
Cached Medicine Technology:DATATRAK to Attend DIA's 23rd Annual EuroMeeting 2
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and easy ... treat specific body parts and muscle groups. , IsoComforter, ... use patented cold therapy machine with the innovative IsoTube design ... injuries. IsoComforter has become the industry leader in cold ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the American ... effort to further promote visibility and adoption of the top ... AMA journals available via its subscription services, EBSCO will now ... , Long known as both a subscription agency and ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... of colon cancer and colon polyps in men, a new ... of Seattle’s Fred Hutchinson Cancer Research Center studied 102 men ... half the participants were asked to exercise, while the rest ... Men who exercised showed less cancer-cell growth compared to men ...
... Studies show that 'Raloxifene' can reduce postmenopausal women with any ... that has been published in the September 1 issue of ... invasive breast cancer immaterial of whether they are at high ... study had also shown that the drug could reduce the ...
... disorder in human faculties" increases dependence on others and ... Wednesday urged researchers to "direct their efforts in bringing ... autism".// ,Equality can be generated by prevention, ... engaging the minds of affected children in productive efforts ...
... program developed by researchers now at the University of ... to study how individuals with sickle cell disease can ... ,The $2.9 million four-year study will ... Center at Chicago Comprehensive Sickle Cell Center by using ...
... said that it will undertake the subjects of brain tumors, ... changes that lead to cancer.// ,The agency has said ... hundreds or thousands of new genes involved in cancer, so ... treat it and tools to diagnose it. ,Acting director ...
... hearings by the Medical Council must be conducted in private, ... recent proposal that will mandate a public hearing in specific ... additional charge over appointments and control of the council. , ... giving the minister the power to appoint all 25 members ...
Cached Medicine News:Health News:Raloxifene Reduces The Risk Of Breast Cancer 2Health News:Raloxifene Reduces The Risk Of Breast Cancer 3Health News:Autistic Children Need Sense of Equality: A.P.J. Abdul Kalam 2Health News:Computer May Improve Pain Relief for Sickle Cell Patients 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: